An Extension Study to Investigate the Long-term Safety and Tolerability of Itepekimab in Adult Participants With Inadequately Controlled Chronic Rhinosinusitis With Nasal Polyps

Exclusion Criteria

• •Participants are excluded from the study if any of the following criteria apply:
• •Diagnosis of a malignancy during parent study, except a squamous or basal cell carcinoma of the skin.
• •Any opportunistic infection during the parent study, such as tuberculosis (TB) or other infections whose nature or course may suggest an immunocompromised status.
• •Anaphylactic reactions or systemic allergic reactions that are related to IMP and require treatment during the parent study.
• •Any other situation that led to a permanent premature IMP discontinuation in parent trials.
• •The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.